Dian Diagnostics Group Co (SZSE:300244) ROCE % : 4.80% (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Dian Diagnostics Group Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Dian Diagnostics Group Co's annualized ROCE % for the quarter that ended in Mar. 2024 was 4.80%.

Dian Diagnostics Group Co ROCE % Historical Data

The historical data trend for Dian Diagnostics Group Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dian Diagnostics Group Co ROCE % Chart

Dian Diagnostics Group Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

15.69

22.59

25.30

25.32

7.96

Dian Diagnostics Group Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															12.48	13.58	9.47	-5.13	4.80

Dian Diagnostics Group Co ROCE % Calculation

Dian Diagnostics Group Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	1048.928	/	( ( (21055.969 - 7747.957)	+	(17939.311 - 4904.781) )	/ 2 )
	=	1048.928	/	( (13308.012	+	13034.53)	/ 2 )
	=	1048.928	/	13171.271
	=	7.96 %

Dian Diagnostics Group Co's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	625.024	/	( ( (17939.311 - 4904.781)	+	(17855.213 - 4871.369) )	/ 2 )
	=	625.024	/	( ( 13034.53	+	12983.844 )	/ 2 )
	=	625.024	/	13009.187
	=	4.80 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Dian Diagnostics Group Co (SZSE:300244) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Dian Diagnostics Group Co ROCE % Related Terms

Thank you for viewing the detailed overview of Dian Diagnostics Group Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Dian Diagnostics Group Co (SZSE:300244) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Dian Diagnostics Group Co Ltd (SZSE:300244) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 329, Jinpeng Street, 5th Floor, Building 2, Xihu District, Zhejiang, Hangzhou, CHN, 310030

Website

http://www.dazd.cn

Dian Diagnostics Group Co Ltd is an independent third-party medical diagnostic service provider that provides diagnostic services outsourcing as its core business. It promotes the development of multi-service areas of medical diagnostic platforms and integrated development strategies for upstream and downstream industry chains, covering medical diagnostic services and diagnostic products.

Dian Diagnostics Group Co (SZSE:300244) Headlines

No Headlines